Eupraxia Pharmaceuticals Files Notice of Shareholder Meeting

Ticker: EPRX · Form: 6-K · Filed: May 15, 2024 · CIK: 1581178

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting, filing-update

Related Tickers: EPRX

TL;DR

Eupraxia Pharma (EPRX) filed a 6-K for their shareholder meeting notice, incorporated into F-10 and S-8 filings.

AI Summary

Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 15, 2024, to report its Notice of Annual General and Special Meeting of Shareholders. This filing is incorporated by reference into their existing Registration Statements on Form F-10 (File No. 333-276586) and Form S-8 (File No. 333-278534). The company is based in Victoria, British Columbia, Canada.

Why It Matters

This filing signals routine corporate governance activities, including the upcoming shareholder meeting, which is a standard procedural step for publicly traded companies.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure regarding a shareholder meeting and does not contain new financial or operational information that would typically alter risk.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to report the Notice of Annual General and Special Meeting of Shareholders for Eupraxia Pharmaceuticals Inc.

When was this Form 6-K filed?

This Form 6-K was filed on May 15, 2024.

What other SEC filings does this 6-K incorporate information into?

Exhibit 99.1 of this Form 6-K is incorporated by reference into Eupraxia Pharmaceuticals Inc.'s Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).

Where is Eupraxia Pharmaceuticals Inc. located?

Eupraxia Pharmaceuticals Inc. is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.

What is the company's standard industrial classification?

The company's standard industrial classification is Pharmaceutical Preparations [2834].

Filing Stats: 229 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-05-15 12:00:30

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 15, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing